Canaccord Genuity analyst John Newman maintained a Buy rating on Palatin Technologies yesterday and set a price target of $3.00.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 24.5% and a 44.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Allogene Therapeutics.
Currently, the analyst consensus on Palatin Technologies is a Strong Buy with an average price target of $2.17, a 442.5% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $2.00 price target.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 24.5% and a 44.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Allogene Therapeutics.
Currently, the analyst consensus on Palatin Technologies is a Strong Buy with an average price target of $2.17, a 442.5% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $2.00 price target.
评论:
BTFD!!!!!!! Wooooooooo